Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217041 · ClinicalTrials.gov registry record
Fluid Status of Dialysis Subjects
A clinical trial, sponsored by HemoCept.
- Completed
- Registry status
- 12
- Enrollment target
NCT07217041: Completed study, sponsored by HemoCept.
NCT07217041 is a clinical trial that has completed, run by HemoCept. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217041 has completed, sponsored by HemoCept.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical pilot study is to evaluate the ability of the device to properly detect the hydration status of the subject through the study of fluid removal data during dialysis and HemoCept device data.
Primary Outcome
The primary end point will be to determine if there is a correlation between HemoCept device data and dry weight changes during dialysis. The primary analysis will be conducted at specific points during dialysis treatment: prior to dialysis, in the middle of the dialysis session, and immediately following the completion of dialysis treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2025-06-09 |
What the finished NCT07217041 record still lists
NCT07217041 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07217041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07217041 about?
NCT07217041 is a clinical study titled "Fluid Status of Dialysis Subjects". The goal of this clinical pilot study is to evaluate the ability of the device to properly detect the hydration status of the subject through the study of fluid removal data during dialysis and HemoCept device data.
What is the current status of trial NCT07217041?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2025-03-19. Estimated completion is 2025-06-09.
Who is sponsoring clinical trial NCT07217041?
This trial is sponsored by HemoCept, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI